Genprex (NASDAQ:GNPX) Stock Price Up 8.1% – Still a Buy?

by · The Markets Daily

Genprex (NASDAQ:GNPX – Get Free Report)’s share price shot up 8.1% during mid-day trading on Friday . The stock traded as high as $2.85 and last traded at $2.66. 1,949,799 shares traded hands during trading, an increase of 28% from the average session volume of 1,518,983 shares. The stock had previously closed at $2.46.

Analysts Set New Price Targets

GNPX has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Genprex to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Stock Report on Genprex

Genprex Price Performance

The stock has a market cap of $8.30 million, a price-to-earnings ratio of -0.10 and a beta of -0.81. The company’s fifty day simple moving average is $2.52 and its two-hundred day simple moving average is $7.53.

Genprex (NASDAQ:GNPX – Get Free Report) last released its quarterly earnings results on Friday, November 14th. The company reported ($5.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($12.50) by $7.50. On average, analysts forecast that Genprex will post -5.7 earnings per share for the current year.

Institutional Investors Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP increased its holdings in Genprex (NASDAQ:GNPX – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the period. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 as of its most recent SEC filing. 14.05% of the stock is owned by institutional investors.

Genprex Company Profile

(Get Free Report)

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.

Featured Stories